Clinical Trials Search
Evaluation of Panobinostat (LBH589) as Maintenance Therapy in Multiple Myeloma Following Autologous Hematopoietic Cell Transplantation
The purpose of this study is to learn more about ways to prevent or delay relapse of multiple myeloma (MM). This study will determine the best dosing schedule of LBH589 maintenance therapy as well as the safety (side effects) and tolerability of LBH589 maintenance therapy after autologous hematopoietic cell transplant (HCT).
To determine tolerability and safety profile of 2 different dosing schedule of single agent panobinostat maintenance therapy for a maximum of 12 intended cycles after autologous HCT in patients with multiple myeloma. We will calculate relative dose intensity (RDI) for each cohort. Secondary objectives: To evaluate the complete response rate to panobinostat maintenance therapy after autologous HCT. To determine the 2-year PFS and OS of autologous HCT followed by panobinostat maintenance therapy in patients with multiple myeloma.